8-K: Allogene Therapeutics Announces $110 Million Registered Direct Offering

Allogene Therapeutics has entered into agreements for a registered direct offering of common stock, expected to generate approximately $110 million in gross proceeds.

Summary

• Allogene Therapeutics has announced a registered direct offering of 37,931,035 shares of its common stock at a price of $2.90 per share.
• The offering is expected to generate gross proceeds of approximately $110 million before deducting underwriting discounts, commissions, and other offering expenses.
• The closing of the offering is anticipated to occur on May 16, 2024, subject to customary closing conditions.
• Goldman Sachs & Co. LLC is acting as the underwriter for the offering.
• Certain directors and executive officers, including Arie Belldegrun, David Chang, and Geoffrey Parker, are participating in the offering, each purchasing 344,828 shares.
• The offering is being made pursuant to an effective registration statement on Form S-3 and an accompanying prospectus supplement.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the capital raise is necessary for the company's operations, it also dilutes existing shareholders. The participation of insiders is a positive sign, but the lack of a premium on the offering price is not particularly encouraging.

Positives

• The offering is expected to provide Allogene with approximately $110 million in gross proceeds, strengthening its financial position.
• The participation of key executives and directors in the offering demonstrates their confidence in the company's future.
• The offering is being conducted through a registered process, providing transparency and compliance with securities regulations.

Negatives

• The offering will dilute existing shareholders' ownership in the company.
• The offering price of $2.90 per share is the same as the closing price on May 13, 2024, suggesting no premium was achieved.
• The company will incur underwriting discounts, commissions, and other offering expenses, reducing the net proceeds.

Risks

• The completion of the offering is subject to customary closing conditions, which may not be satisfied.
• Market conditions could impact the success of the offering and the company's stock price.
• The company's actual results may differ materially from its expectations due to various factors, including those disclosed in its SEC filings.

Future Outlook

The company expects to complete the offering on May 16, 2024, and use the net proceeds as specified in the prospectus. The company disclaims any obligation to update forward-looking statements.

Management Comments

• David Chang, M.D., Ph.D., President and CEO, signed the report on behalf of the company.
• Geoffrey Parker, Chief Financial Officer, signed the underwriting agreement on behalf of the company.

Industry Context

This capital raise is typical for a biotechnology company like Allogene, which requires significant funding for research and development. The company is likely using the funds to advance its pipeline of cell therapies.

Comparison to Industry Standards

• The offering size of $110 million is a moderate amount for a biotech company at this stage, with some companies raising significantly more and others less depending on their pipeline and cash burn.
• The direct offering structure is a common method for biotech companies to raise capital, allowing them to quickly access funds from institutional investors and insiders.
• The pricing at the market close price is typical for these types of offerings, as it avoids the risk of pricing the offering at a discount that could negatively impact the stock price.

Related Party Transactions

• Arie Belldegrun, David Chang, and Geoffrey Parker, all directors or executive officers, are purchasing shares in the offering.

Stakeholder Impact

• Shareholders will experience dilution due to the issuance of new shares.
• The company will have additional capital to fund its operations and research.
• The offering may impact the company's stock price in the short term.

Next Steps

• The company will complete the closing of the offering on May 16, 2024.
• The company will use the net proceeds from the offering as specified in the prospectus.

Key Dates

Keywords

registered direct offering, common stock, capital raise, equity financing, Goldman Sachs, Allogene Therapeutics, securities offering